BioNTech can quickly tailor its omicron vaccine: CEO

FRANKFURT, Dec 3 (Reuters) – German biopharmaceutical company BioNTech should be able to tailor its coronavirus vaccine relatively quickly in response to the emergence of the omicron variant, CEO Ugur Sahin said at the Reuters Next conference on Friday.

Sahin also said that vaccines must continue to provide protection against serious diseases despite mutations in the virus.

To view the Reuters Next conference, register here

(Reporting by Ludwig Burger and Josephine Mason; edited in Spanish by Marion Giraldo)

Article Source